BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 38487523)

  • 1. Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials.
    Qi C; Zhang P; Liu C; Zhang J; Zhou J; Yuan J; Liu D; Zhang M; Gong J; Wang X; Li J; Zhang X; Li N; Peng X; Liu Z; Yuan D; Baffa R; Wang Y; Shen L
    J Clin Oncol; 2024 May; ():JCO2302314. PubMed ID: 38788174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
    Du J; Zhang Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report.
    Zhong G; Zhang X; Guo Z; Gao Y; Zhao B; Liu X; Chen L; Qiao J; Yu C; Wang L; Li Y; Yu L
    Front Immunol; 2024; 15():1325860. PubMed ID: 38487523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells.
    Botta GP; Chao J; Ma H; Hahn M; Sierra G; Jia J; Hendrix AY; Nolte Fong JV; Ween A; Vu P; Miller A; Choi M; Heyman B; Daniels GA; Kaufman D; Jamieson C; Li Z; Cohen E
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38316518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
    Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
    J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Report: A rare case of recurrent ascites after anti-Claudin18.2 antibody therapy for metastatic gastric cancer while responding sustainingly.
    Liu J; Jiang D; Lei Q; Zhu Q; Zhu H
    Front Oncol; 2023; 13():1211668. PubMed ID: 37681021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
    Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
    Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models.
    Yuan Y; Fan J; Liang D; Wang S; Luo X; Zhu Y; Liu N; Xiang T; Zhao X
    Transl Oncol; 2024 Jan; 39():101803. PubMed ID: 37897831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer.
    Qi C; Xie T; Zhou J; Wang X; Gong J; Zhang X; Li J; Yuan J; Liu C; Shen L
    J Hematol Oncol; 2023 Sep; 16(1):102. PubMed ID: 37689733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer.
    Fan J; Yu Y; Yan L; Yuan Y; Sun B; Yang D; Liu N; Guo J; Zhang J; Zhao X
    J Hematol Oncol; 2023 Jul; 16(1):77. PubMed ID: 37475048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Growth Suppression of Pancreatic Cancer Orthotopic Xenograft Model by CEA-Targeting CAR-T Cells.
    Sato O; Tsuchikawa T; Kato T; Amaishi Y; Okamoto S; Mineno J; Takeuchi Y; Sasaki K; Nakamura T; Umemoto K; Suzuki T; Wang L; Wang Y; Hatanaka KC; Mitsuhashi T; Hatanaka Y; Shiku H; Hirano S
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.
    Wang X; Zhang CS; Dong XY; Hu Y; Duan BJ; Bai J; Wu YY; Fan L; Liao XH; Kang Y; Zhang P; Li MY; Xu J; Mao ZJ; Liu HT; Zhang XL; Tian LF; Li EX
    World J Gastrointest Oncol; 2022 Jul; 14(7):1252-1264. PubMed ID: 36051096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients.
    Zhang Z; Liu X; Zhou L; Zhang M; Liang Z
    Histol Histopathol; 2022 Oct; 37(10):1031-1040. PubMed ID: 35656795
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.